Skip to main content

Illumina's Q3 Revenue Surges 82 Percent on Strong Product Sales, Though Profit Slides

NEW YORK (GenomeWeb News) — Illumina yesterday said third-quarter revenues bolted 82 percent and R&D spending rose 160 percent, though profits fell 10 percent.
Total receipts for the three months ended Sept. 30 increased to $97.5 million from $53.5 million year over year.
Product revenues leapt to $90 million from $46.9 million, while service and other revenue rose to $7.4 million from $6.4 million year over year.
R&D spending increased to $19.8 million from $7.7 million in the year-ago period, including around $13.2 million in non-cash stock compensation expenses.
Profit for the quarter declined to $14.5 million from $16.2 million.
Illumina said it had around $352.8 million in cash, equivalents, and short-term investments as of Sept. 30.
The company raised its expected full-year 2007 revenue to between $354 million and $358 million, which is $16 million higher than projections it made in July, or around 17 percent more than it projected at the beginning of the year.
Illumina expects fourth-quarter revenue to be between $100 million and $104 million, or as much as 69 percent over the same period last year.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.